Skip to Content
  • Title
    Director
  • Affiliation
    FDA's Office of Hematology and Oncology Products

Rarely does one hear anybody celebrate the FDA. But lately the agency’s gatekeeper for cancer drugs is getting nearly universal praise for his effort to speed promising medications to market. In 2014 the FDA approved the greatest number of novel drugs in almost 20 years. Under Pazdur’s leadership, says Len Lichtenfeld of the American Cancer Society, “the FDA has been more responsive to the needs of cancer patients.”

Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access